| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae4703d6bdd87589cbb201f57d96132c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09ca043d7e596facff1f44b746e2f4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-24087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6489
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2008-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c952d8178a43562945ad8b4bf57aec35 |
| publicationDate |
2008-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009001743-A1 |
| titleOfInvention |
Novel adamts-13 mutant |
| abstract |
Disclosed are: a method for enhancing the enzymatic activity of ADAMTS-13 and/or a method for reducing the reactivity of ADAMTS-13 with an anti-ADAMTS-13 neutralizing antibody; and an ADAMTS-13 mutant which is produced by the method. The method is characterized by substituting at least one charged amino acid residue located in a disintegrin-like domain, a cysteine-rich domain or a spacer domain of ADAMTS-13 other than the following amino acid residues by another amino acid residue: an arginine residue at position-326, an aspartic acid residue at position-330, an aspartic acid residue at position-343 and an arginine residue at position-349 in the disintegrin-like domain; an aspartic acid residue at position-480, an arginine residue at position-488, an arginine residue at position-498, an arginine residue at position-507, an aspartic acid residue at position-533 and an aspartic acid residue at position-543 in the cysteine-rich domain; and a glutamic acid residue at position-641 and an arginine residue at position-660 in the spacer domain. Further disclosed is a therapeutic agent for a thrombotic disease, which comprises the ADAMTS-13 mutant produced by the method as an active ingredient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015044171-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013096793-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013500711-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9546360-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015147815-A |
| priorityDate |
2007-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |